Skip to main content
Clinical Trials/NCT06325527
NCT06325527
Not yet recruiting
Not Applicable

Shanghai Cognitive Impairment Study of the Elderly Population: YuGarden Cohort

Ruijin Hospital1 site in 1 country1,872 target enrollmentApril 1, 2024

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Alzheimer Disease
Sponsor
Ruijin Hospital
Enrollment
1872
Locations
1
Primary Endpoint
Incidence of cognitive impairment
Status
Not yet recruiting
Last Updated
2 years ago

Overview

Brief Summary

The goal of this prospective observational research with an 8-year follow-up is to study the cognitive changes in the elderly in YuGarden community, Shanghai, China.

The main questions it aims to answer are:

  • incidence of cognitive impairment in community (converting to mild cognitive impairment or Alzheimer's disease)
  • to build a predictive model for the progression of cognitive impairment

Detailed Description

This study is a prospective observational study which involves a large sample cohort of the elderly aged 60 to 85 years in YuGarden community, Shanghai, China, with an 8-year follow-up. Demographic information, peripheral organs evaluation (facial expression, hearing, OCT angiography), cognitive tests (MMSE, ADL), biospecimen (peripheral blood, urine, feces, gingival crevicular fluid), speech information, neuroimaging (MRI, PET) and electroencephalogram (EEG) will be collected and analyzed. Follow-up visits will be conducted twice a year for 4 visits and each visit includes cognitive tests, biospecimen collection, speech test, MRI and EEG. The primary outcome is the incidence of cognitive impairment indicating people who convert to mild cognitive impairment (MCI) or Alzheimer's disease (AD). Furthermore, a predictive model for the progression of cognitive impairment will be constructed.

Registry
clinicaltrials.gov
Start Date
April 1, 2024
End Date
June 1, 2031
Last Updated
2 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • The participants are community-dwelling elderly people living in Yuyuan community, Shanghai, aged 60-85 years old, with no gender restriction.
  • Non-AD patients.
  • The participants can complete the cognitive tests, biological sample collection, speech tests, neuroimaging examinations, and cooperate with the implementation of the whole process of research.
  • The participants agree to participate in this study and sign the informed consent form.

Exclusion Criteria

  • Participants who are suffering from severe mental illness, tumor cachexia, severe liver and kidney dysfunction and other serious physical diseases and unable to cooperate with the examination.
  • Participants who have visual or auditory impairment that hampers the completion of related examination.
  • Situations when magnetic resonance imaging or other examinations are contraindicated.

Outcomes

Primary Outcomes

Incidence of cognitive impairment

Time Frame: 8 years

Number of participants who covert to mild cognitive impairment (MCI) or AD will be recorded to calculate the incidence.

Secondary Outcomes

  • The change of Barthel Index for Activities of Daily Living (ADL)(baseline, 2 year, 4 year, 6 year, 8 year)
  • Positron emission tomography (PET)(baseline)
  • The change of feces biomarkers(baseline, 2 year, 4 year, 6 year, 8 year)
  • The change of blood biomarkers(baseline, 2 year, 4 year, 6 year, 8 year)
  • The change of gingival crevicular fluid biomarkers(baseline, 2 year, 4 year, 6 year, 8 year)
  • The change of structural MRI(baseline, 2 year, 4 year, 6 year, 8 year)
  • The change of magnetic susceptibility(baseline, 2 year, 4 year, 6 year, 8 year)
  • The change of Mini-Mental State Examination (MMSE)(baseline, 2 year, 4 year, 6 year, 8 year)
  • The change of functional MRI(baseline, 2 year, 4 year, 6 year, 8 year)
  • The change of urine biomarkers(baseline, 2 year, 4 year, 6 year, 8 year)
  • The change of electroencephalogram (EEG)(baseline, 2 year, 4 year, 6 year, 8 year)
  • The change of speech information(baseline, 2 year, 4 year, 6 year, 8 year)
  • The change of perfusion MR imaging(baseline, 2 year, 4 year, 6 year, 8 year)

Study Sites (1)

Loading locations...

Similar Trials